Combining Mass Cytometry Data by CyTOFmerge Reveals Additional Cell Phenotypes in the Heterogeneous Ovarian Cancer Tumor Microenvironment: A Pilot Study

Author:

Thomsen Liv Cecilie Vestrheim123ORCID,Kleinmanns Katrin1ORCID,Anandan Shamundeeswari12,Gullaksen Stein-Erik1ORCID,Abdelaal Tamim45,Iversen Grete Alrek2,Akslen Lars Andreas67ORCID,McCormack Emmet18ORCID,Bjørge Line12ORCID

Affiliation:

1. Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, 5021 Bergen, Norway

2. Department of Obstetrics and Gynecology, Haukeland University Hospital, 5021 Bergen, Norway

3. Norwegian Institute of Public Health, 5015 Bergen, Norway

4. Delft Bioinformatics Laboratory, Delft University of Technology, 2628XE Delft, The Netherlands

5. Department of Radiology, Leiden University Medical Center, 2333ZA Leiden, The Netherlands

6. Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, 5021 Bergen, Norway

7. Department of Pathology, Haukeland University Hospital, 5021 Bergen, Norway

8. Centre for Pharmacy, Department of Clinical Science, University of Bergen, 5021 Bergen, Norway

Abstract

The prognosis of high-grade serous ovarian carcinoma (HGSOC) is poor, and treatment selection is challenging. A heterogeneous tumor microenvironment (TME) characterizes HGSOC and influences tumor growth, progression, and therapy response. Better characterization with multidimensional approaches for simultaneous identification and categorization of the various cell populations is needed to map the TME complexity. While mass cytometry allows the simultaneous detection of around 40 proteins, the CyTOFmerge MATLAB algorithm integrates data sets and extends the phenotyping. This pilot study explored the potential of combining two datasets for improved TME phenotyping by profiling single-cell suspensions from ten chemo-naïve HGSOC tumors by mass cytometry. A 35-marker pan-tumor dataset and a 34-marker pan-immune dataset were analyzed separately and combined with the CyTOFmerge, merging 18 shared markers. While the merged analysis confirmed heterogeneity across patients, it also identified a main tumor cell subset, additionally to the nine identified by the pan-tumor panel. Furthermore, the expression of traditional immune cell markers on tumor and stromal cells was revealed, as were marker combinations that have rarely been examined on individual cells. This study demonstrates the potential of merging mass cytometry data to generate new hypotheses on tumor biology and predictive biomarker research in HGSOC that could improve treatment effectiveness.

Funder

Helse Vest RHF

Helse Bergen HF

Norwegian Cancer Society

Research Council of Norway through its Centers of Excellence funding scheme

H2020 program MSCA-ITN

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Reference59 articles.

1. Ovarian cancer in the world: Epidemiology and risk factors;Momenimovahed;Int. J. Women’s Health,2019

2. Larsen, I.K. (2021). Cancer in Norway 2020—Cancer Incidence, Mortality, Survival and Prevalence in Norway, Cancer Registry of Norway.

3. Evolving Concepts in the Management of Newly Diagnosed Epithelial Ovarian Cancer;Gourley;J. Clin. Oncol.,2019

4. Current status and future directions of cancer immunotherapy;Zhang;J. Cancer,2018

5. Hot or Not: Tumor Mutational Burden (TMB) as a Biomarker of Immunotherapy Response in Genitourinary Cancers;Halbert;Urology,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3